AWP
TSHA icon

Abacus Wealth Partners’s Taysha Gene Therapies TSHA Stock Holding History

Abacus Wealth Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-58,241
Closed -$260K – 503
2026
Q1 		$260K Buy
58,241
+3,068
+6% +$14.3K 0.02% 403
2025
Q4 		$303K Buy
+55,173
New +$268K 0.03% 338

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Abacus Wealth Partners's TSHA Position: Q2 2026 in Review

Abacus Wealth Partners sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 58,241 shares — an estimated $260K sold.

Abacus Wealth Partners first reported a position in TSHA in Q4 2025 and held it in 2 quarters. The position peaked at $303K in Q4 2025. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Abacus Wealth Partners reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Abacus Wealth Partners sold 58,241 Taysha Gene Therapies shares in Q2 2026, an estimated $260K.
  • Abacus Wealth Partners first reported a position in Taysha Gene Therapies in Q4 2025 and held it in 2 quarters.
  • Abacus Wealth Partners's Taysha Gene Therapies position peaked at $303K in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.